KOERS GALAPAGOS 2015

1. [verwijderd] 8 mei 2015 20:12

   auteur info

   • [verwijderd]

     Lid sinds: 01 jan 0001

     Laatste bezoek: 01 jan 0001

   • Aanbevelingen

     Ontvangen: 0

     Gegeven: 0

   •    Aantal posts: 0

   Er is van meerdere kanten geopperd dat ze mogelijk kansrijke moleculen of onderzoeksprogrammas opkopen, misschien is een kleine overname dan wel goedkoper. Er zijn tig bedrijven met een marktwaarde < 100 miljoen, als het dan toch over eeuwige roem gaat, als iemand dit goed voorspelt verdien je dst zeker :) Of gaan ze het allemaal nodig hebben voor de 2 programmas die ze zelf op de markt willen brengen....
2. [verwijderd] 8 mei 2015 20:19

   auteur info

   • [verwijderd]

     Lid sinds: 01 jan 0001

     Laatste bezoek: 01 jan 0001

   • Aanbevelingen

     Ontvangen: 0

     Gegeven: 0

   •    Aantal posts: 0

   quote:

   chicken little schreef op 8 mei 2015 19:34:

   zie ik daar staan $42.43??
   

   Dit is de richtprijs. Veel interesse wordt die hoger, weinig wordt die lager.
3. [verwijderd] 8 mei 2015 20:23

   auteur info

   • [verwijderd]

     Lid sinds: 01 jan 0001

     Laatste bezoek: 01 jan 0001

   • Aanbevelingen

     Ontvangen: 0

     Gegeven: 0

   •    Aantal posts: 0

   Waarom zouden ze geld verspillen aan overnames? Goede moleculen zijn onbetaalbaar; prut is er genoeg te koop. Daarnaast hebben ze zelf één van de beste discovery platforms die er bestaan.
   
   fc
   
   Daarnaast:
   The principal purposes of the global offering are to increase our financial flexibility to advance our clinical pipeline, create a public market for our securities in the United States and facilitate our future access to the U.S. public equity markets. We currently expect to use the net proceeds from the global offering as follows:
   
   . approximately $80 million to advance our CF program combination therapy GLPG1837, GLPG2222 and a second corrector candidate expected to be identified later in 2015) in CF until the end of Phase 2 clinical development;
   
   . approximately $65 million to advance our IBD program (GLPG1205) until the end of Phase 2 clinical development; and
   
   . approximately $30 million to advance the discovery and development of our earlier stage programs, including our IPF program (GLPG1690).
   
   We expect to use the remainder of any net proceeds from the global offering for working capital and other general corporate purposes.
   
   Read more: www.nasdaq.com/markets/ipos/company/g...
4. egeltjemetstekel 8 mei 2015 20:30

   auteur info

   • egeltjemetstekel

     Lid sinds: 28 jul 2011

     Laatste bezoek: 28 feb 2025

   • Aanbevelingen

     Ontvangen: 1673

     Gegeven: 1273

   •    Aantal posts: 11.287

   quote:

   chicken little schreef op 8 mei 2015 19:34:

   zie ik daar staan $42.43??
   

   ja precies!
   Dat is handig want dan kan j leek mooi verifiëren op z'n raad de koers lijstje wie dat goed geraden heeft. ;-)
   
   Maar donderdag 14 mei Hemelvaartsdag gaan we het dus beleven.
   Ik ben benieuwd.
5. diederique 8 mei 2015 20:32

   auteur info

   • diederique

     Lid sinds: 01 mrt 2004

     Laatste bezoek: 03 okt 2024

   • Aanbevelingen

     Ontvangen: 913

     Gegeven: 218

   •    Aantal posts: 8.547

   Biotech to Remain Strong Because Science is Solid, CEOs Say
   
   Messrs. Leschly and Schenkein said the surge of biotech IPOs and the rise in the stock of many of those companies doesn’t mean the sector is in a bubble.
   
   What once seemed like science fiction–for example, using a virus to deliver new genes to a patient’s body–is now reality, and investors want to be part of it every bit as much as dangerously sick patients do.
   
   “A decade ago, stuff just didn’t get to market,” Mr. Schenkein said. “In the 2000s, most drugs failed because they didn’t work. But the science has changed dramatically.”
   
   blogs.wsj.com/venturecapital/2015/05/...
6. [verwijderd] 8 mei 2015 20:41

   auteur info

   • [verwijderd]

     Lid sinds: 01 jan 0001

     Laatste bezoek: 01 jan 0001

   • Aanbevelingen

     Ontvangen: 0

     Gegeven: 0

   •    Aantal posts: 0

   Wij van wc-eend....
7. Sentiment 8 mei 2015 20:54

   auteur info

   • Sentiment

     Lid sinds: 13 nov 2003

     Laatste bezoek: 08 nov 2024

   • Aanbevelingen

     Ontvangen: 1191

     Gegeven: 631

   •    Aantal posts: 10.257

   quote:

   egeltjemetstekel schreef op 7 mei 2015 03:35:

   ik vond op marketwatch.com een pagina over galapagos
   er wordt gemeld dat het nu nog pre-ipo is op de nasdag
   er staat een prijs van $42.43 usdollar bij (weet niet of dat al up to date is)
   
   verder niet veel info denk ik
   
   maar hier is de link: www.marketwatch.com/investing/stock/G...
   

   Zal het dan toch $42,43 worden???
8. [verwijderd] 8 mei 2015 21:10

   auteur info

   • [verwijderd]

     Lid sinds: 01 jan 0001

     Laatste bezoek: 01 jan 0001

   • Aanbevelingen

     Ontvangen: 0

     Gegeven: 0

   •    Aantal posts: 0

   quote:

   TheBateman schreef op 8 mei 2015 19:41:

   42,43 dollar is Euro 37.7752
   

   als het 37.7752 zou zijn, dan heeft mick jagger juist geraden.
   
9. [verwijderd] 8 mei 2015 21:11

   auteur info

   • [verwijderd]

     Lid sinds: 01 jan 0001

     Laatste bezoek: 01 jan 0001

   • Aanbevelingen

     Ontvangen: 0

     Gegeven: 0

   •    Aantal posts: 0

   quote:

   Sentiment schreef op 8 mei 2015 20:54:

   [...]Zal het dan toch $42,43 worden???
   

   Volgens mij was dat simpelweg de slotkoers op 4 mei
10. mickjagger2 8 mei 2015 21:15

    auteur info

    • mickjagger2

      Lid sinds: 01 okt 2006

      Laatste bezoek: 14 mei 2024

    • Aanbevelingen

      Ontvangen: 547

      Gegeven: 653

    •    Aantal posts: 3.808

    quote:

    grrrrrrrrrrrr pffffff zucht schreef op 8 mei 2015 21:10:

    [...]
    als het 37.7752 zou zijn, dan heeft mick jagger juist geraden.
    
    

    Its only rock and roll and i like it..
11. egeltjemetstekel 8 mei 2015 22:31

    auteur info

    • egeltjemetstekel

      Lid sinds: 28 jul 2011

      Laatste bezoek: 28 feb 2025

    • Aanbevelingen

      Ontvangen: 1673

      Gegeven: 1273

    •    Aantal posts: 11.287

    Dat is mooi
    Maar ik had de dollarkoers goed
    Kwam alleen op een ander euro bedrag omdat
    De dollar euro koers toen anders was dan nu
    (Heb ook nog een halve cent naar boven afgerond)
    En die dollar euro koers is op moment van ipo vast weer anders
    Dus het blijft afwachten
    Het zal me benieuwen....
    Maar ik gun het jou wel hoor mick!
12. NielsjeB 8 mei 2015 23:00

    auteur info

    • NielsjeB

      Lid sinds: 29 aug 2014

      Laatste bezoek: 28 feb 2025

    • Aanbevelingen

      Ontvangen: 3298

      Gegeven: 12388

    •    Aantal posts: 4.648

    quote:

    asti schreef op 8 mei 2015 21:11:

    [...]
    Volgens mij was dat simpelweg de slotkoers op 4 mei
    

    Exactly. Jongens, er is hier uitgebreid gepost dat de IPO zoals ingediend door Galapagos simpelweg de slotkoers van 4 mei als referentiekoers gebruikt.
    
    Lees het volgende uit het IPO amendement 3. Rest mag ook, maar is wat veel:
    
    Each $1.00 (€0.90) increase or decrease in the assumed public offering price of $42.43 per ADS in the U.S. offering and €38.05 per ordinary share in the European private placement, the closing price of our ordinary shares on Euronext Amsterdam on May 4, 2015, would increase or decrease each of as adjusted cash and cash equivalents, total assets and total shareholders’ equity by approximately $4.4 (€3.9) million, assuming that the number of shares and ADSs offered by us, as set forth on the cover page of this prospectus, remains the same and after deducting underwriting discounts and commissions. We may also increase or decrease the number of shares and ADSs we are offering. Each increase or decrease of 1,000,000 shares and ADSs in the aggregate number of shares and ADSs offered by us would increase or decrease each of as adjusted cash and cash equivalents, total assets and total shareholders’ equity by approximately $39.5 (€35.4) million, assuming that the assumed public offering price remains the same, and after deducting underwriting discounts and commissions. Each increase of 1,000,000 shares and ADSs in the aggregate number of shares and ADSs offered by us together with a concomitant $1.00 (€0.90) increase in the assumed public offering price of $42.43 per ADS in the U.S. offering and €38.05 per ordinary share in the European private placement, the closing price of our ordinary shares on Euro next Amsterdam on May 4, 2015, would increase each of as adjusted cash and cash equivalents, total assets and total shareholders’ equity by approximately $44.8 (€40.2) million, after deducting underwriting discounts and commissions. Each decrease of 1,000,000 shares and ADSs in the aggregate number of shares and ADSs offered by us together with a concomitant $1.00 (€0.90) decrease in the assumed public offering price of $42.43 per ADS in the U.S. offering and €38.05 per ordinary share in the European private placement, the closing price of our ordinary shares on Euronext Amsterdam on May 4, 2015, would decrease each of as adjusted cash and cash equivalents, total assets and total shareholders’ equity by approximately $42.9 (€38.5) million, after deducting underwriting discounts and commissions. The as adjusted information discussed above is illustrative only and will adjust based on the actual public offering price, the actual number of ordinary shares and ADSs offered by us, and other terms of the global offering determined at pricing.
    
    www.sec.gov/Archives/edgar/data/14218...
    
    Ook het tweede stukje van de quote is interessant, er kan nl. nog aan behoorlijk wat knoppen gedraaid worden. Laten we onszelf laten verrassen, liefst aangenaam natuurlijk.
13. NielsjeB 8 mei 2015 23:04

    auteur info

    • NielsjeB

      Lid sinds: 29 aug 2014

      Laatste bezoek: 28 feb 2025

    • Aanbevelingen

      Ontvangen: 3298

      Gegeven: 12388

    •    Aantal posts: 4.648

    quote:

    FatCool schreef op 8 mei 2015 20:23:

    Read more: www.nasdaq.com/markets/ipos/company/g...
    

    Goeie link FatCool, verplicht leesvoer. Mooie samenvatting van de IPO.
14. NielsjeB 8 mei 2015 23:11

    auteur info

    • NielsjeB

      Lid sinds: 29 aug 2014

      Laatste bezoek: 28 feb 2025

    • Aanbevelingen

      Ontvangen: 3298

      Gegeven: 12388

    •    Aantal posts: 4.648

    quote:

    j leek schreef op 8 mei 2015 17:08:

    [...]
    Dan worden er diverse forum leden verwijderd!
    

    Valt wel mee hoor, meer een soort ongeschreven regel. Geen probleem verder, maar verwacht dan wel de reacties zoals je ze kreeg ;)
15. [verwijderd] 9 mei 2015 03:37

    auteur info

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    Hey all, how about Biocartis [Brussels Stock Exchange] does it have the same potential as Galapagos? I'm not sure, bit of a gamble, what do you think?
16. [verwijderd] 9 mei 2015 06:29

    auteur info

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    We estimate that we will receive net proceeds from the global offering of
    approximately $183.3 (€164.3) million, assuming a public offering price of
    $42.43 per ADS in the U.S. offering and €38.05 per ordinary share in the
    European private placement, the closing price of our ordinary shares on Euronext
    Amsterdam on May 4, 2015, after deducting underwriting discounts and commissions
    and estimated offering expenses payable by us, and assuming no exercise of the
    underwriters’ option to purchase additional ordinary shares and ADSs. If the
    underwriters exercise in full their option to purchase additional ADSs in the
    U.S. offering and additional ordinary shares in the European private placement,
    we estimate that we will receive net proceeds from the global offering of
    approximately $211.2 (€189.4) million, assuming a public offering price of
    $42.43 per ADS in the U.S. offering and €38.05 per ordinary share in the
    European private placement, the closing price of our ordinary shares on Euronext
    Amsterdam on May 4, 2015, after deducting underwriting discounts and commissions
    and estimated offering expenses payable by us.
    
    
17. [verwijderd] 9 mei 2015 06:29

    auteur info

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    
    A $1.00 (€0.90) increase (decrease) in the assumed public offering price of
    $42.43 per ADS in the U.S. offering and €38.05 per ordinary share in the
    European private placement would increase (decrease) our net proceeds from the
    global offering by $4.4 (€3.9) million, assuming the number of shares and ADSs
    offered by us, as set forth on the cover page of this prospectus, remains the
    same and after deducting underwriting discounts and commissions. Each increase
    or decrease of 1,000,000 shares and ADSs in the aggregate number of shares and
    ADSs offered by us would increase or decrease the net proceeds to us from the
    sale of the shares and ADSs we are offering by $39.5 (€35.4) million, assuming
    that the assumed public offering price remains the same and after deducting
    underwriting discounts and commissions. Each increase of 1,000,000 shares and
    ADSs in the aggregate number of shares and ADSs offered by us together with a
    concomitant $1.00 (€0.90) increase in the assumed public offering price of
    $42.43 per ADS in the U.S. offering and €38.05 per ordinary share in the
    European private placement, would increase the net proceeds to us from the sale
    of the shares and ADSs we are offering by $44.8 (€40.2) million, after deducting
    underwriting discounts and commissions. Each decrease of 1,000,000 shares and
    ADSs in the aggregate number of shares and ADSs offered by us together with a
    concomitant $1.00 (€0.90) decrease in the assumed public offering price of
    $42.43 per ADS in the U.S. offering and €38.05 per ordinary share in the
    European private placement would decrease the net proceeds to us from the sale
    of the shares and ADSs we are offering by $42.9 (€38.5) million, after deducting
    underwriting discounts and commissions. The actual net proceeds payable to us
    will adjust based on the actual number of shares and ADSs offered by us, the
    actual public offering price and other terms of the global offering determined
    at pricing.
18. [verwijderd] 9 mei 2015 06:30

    auteur info

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    The principal purposes of the global offering are to increase our financial
    flexibility to advance our clinical pipeline, create a public market for our
    securities in the United States and facilitate our future access to the U.S.
    public equity markets. We currently expect to use the net proceeds from the
    global offering as follows:
    
    . approximately $80 million to advance our CF program combination therapy
    (GLPG1837, GLPG2222 and a second corrector candidate expected to be identified
    later in 2015) in CF until the end of Phase 2 clinical development;
    
    . approximately $65 million to advance our IBD program (GLPG1205) until the end
    of Phase 2 clinical development; and
    
    . approximately $30 million to advance the discovery and development of our
    earlier stage programs, including our IPF program (GLPG1690).
    
    We expect to use the remainder of any net proceeds from the global offering for
    working capital and other general corporate purposes.
    
    We may also use a portion of the net proceeds to in-license, acquire or invest
    in complementary technologies, products or assets, either alone or together with
    a collaboration partner. However, we have no current plan, commitments or
    obligations to do so.
    
    Based on our current operational plans and assumptions, we expect that the net
    proceeds from the global offering, combined with our current operating capital,
    will be sufficient to support the advancement of our research and development
    programs until the end of 2017. However, there can be no assurance that these
    expectations will be correct.
19. [verwijderd] 9 mei 2015 06:31

    auteur info

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    We currently have no specific plans as to how the net proceeds from the global
    offering will be allocated beyond the uses specified above, and therefore
    management will retain discretion to allocate the remainder of the net proceeds
    of the global offering among these uses.
    
    This expected use of the net proceeds from the global offering represents our
    intentions based upon our current plans and business conditions. As of the date
    of this prospectus, we cannot predict with certainty all of the particular uses
    for the net proceeds to be received upon the completion of the global offering
    or the amounts that we will actually spend on the uses set forth above. The
    amounts and timing of our actual expenditures and the extent of clinical
    development may vary significantly depending on numerous factors, including the
    progress of our development efforts, the status of and results from pre-clinical
    studies and any ongoing clinical trials or clinical trials we may commence in
    the future, as well as any collaborations that we may enter into with third
    parties for our product candidates and any unforeseen cash needs. For example,
    in the event that AbbVie does not elect to in-license filgotinib in the second
    half of 2015 under our collaboration agreement with AbbVie, we may elect to use
    a portion of the net proceeds from the global offering to advance filgotinib on
    our own. As a result, our management will retain broad discretion over the
    allocation of the net proceeds from the global offering.
    
    Pending our use of the net proceeds from the global offering, we intend to
    invest the net proceeds in a variety of capital preservation investments,
    including short-term, investment-grade, interest-bearing instruments.
20. [verwijderd] 9 mei 2015 06:37

    auteur info

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    €38,05/$42,34 om mee te beginnen en kan $1 hoger of lager uitkomen.
    Ik schat in dat de emissie overschreven zal worden en de uiteindelijke emissiekoers rond de $43 zal uitkomen.
    Zeker voor degene die al langer in Galapagos zitten een prima emissie!